Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Overig’

FDA approves Pfizer’s abuse-deterrent opioid painkiller

Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  

Bron: InPharm.com Meer lezen »

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.

Bron: World Pharma News Meer lezen »

Teva Pharma’s Cinqaero receives European marketing approval

Teva Pharmaceutical Industries Ltd. announced that the European Commission has granted marketing authorization for Cinqaero (reslizumab) in the 28 countries of the European Union (EU).

Bron: Pharma Biz Meer lezen »

De toekomst van contentmarketing is (ook) marktonderzoek

“Wat is de toekomst van content marketing?” Het is een vraag die ik regelmatig voorbij zie komen (en die mij ook regelmatig gesteld wordt), zeker nu het onderwerp de hype voorbij is.

Bron: marketingfacts.nl Meer lezen »

GSK, Roche and Novo back $86 million immune-oncology startup

Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its development of anti-CD47 antibodies, including advanced proof-of-concept human trials for its lead drug candidate, an anti-CD47 immune checkpoint inhibitor.

Bron: InPharm.com Meer lezen »

ViiV Healthcare launches Phase III trial for combo HIV treatment

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) as a combination treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.  

Bron: InPharm.com Meer lezen »

Vertex stumbles in Phase III cystic fibrosis trials

Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in cystic fibrosis, with one study in patients with specific mutations set to be cancelled.  

Bron: InPharm.com Meer lezen »

Ouderen missen kennis over wat ze waarom slikken

Ouderen die veel medicijnen moeten gebruiken, weten vaak niet waarom ze die middelen krijgen. En slikken ze dan geregeld niet.

Bron: nos.nl Meer lezen »

Sanofi launches dengue immunisation program in Brazil

Sanofi has announced that it has initiated the first dengue immunisation public program in the Americas, with 500,000 individuals set to receive Dengvaxia dengue vaccine over the next three weeks.  

Bron: InPharm.com Meer lezen »

Novartis invests €100 million to expand French manufacturing plant

Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of Biotechnology facility with a €100 million investment over four years.

Bron: InPharm.com Meer lezen »

« Oudere artikelen | Nieuwere artikelen »